Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pyxis Oncology, Inc.PYXS · Entity 5986 | Prin Fin & Acct Officer | March 24, 2026 | March 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pyxis Oncology, Inc.
Report date March 24, 2026 · Filed March 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 512,882 |
Reported balance
After 2026-03-24 transaction · row 1
1 source rowRow 1 · 2026-03-24 · Grant · Acquired 109,461 · Balance 512,882 F1: Represents restricted stock units that vest 25% on March 31, 2026, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-03-24 | Direct | 262,635 |
Reported balance
After 2026-03-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-24 · Grant · Acquired 262,635 · Balance 262,635 F2: The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 24, 2026 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued emmployment through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest 25% on March 31, 2026, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
F2: The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 24, 2026 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued emmployment through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 24, 2026 Filed Mar 25, 2026 21:17 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 262,635 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001193125-26-124380 · ownership.xml · derivative · entry 2 Wadhane Jitendra · CIK 0001941706 · Prin Fin & Acct Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,635 Underlying: Common Stock · 262,635 shares Expires 2036-03-24 F2 · derivative.exercise_date: The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 24, 2026 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued emmployment through the applicable vesting date. Read SEC document |
| March 24, 2026 Filed Mar 25, 2026 21:17 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 109,461 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-124380 · ownership.xml · nonDerivative · entry 1 Wadhane Jitendra · CIK 0001941706 · Prin Fin & Acct Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 512,882 F1 · shares: Represents restricted stock units that vest 25% on March 31, 2026, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 13:04 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 263,782 | $0.98 Strike: $0.98 | $258,506.36 |
DisclosureSEC source: 0000950170-25-048902 · ownership.xml · derivative · entry 1 Wadhane Jitendra · CIK 0001941706 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,782 Underlying: Common Stock · 263,782 shares Expires 2035-03-31 F1 · derivative.exercise_date: The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 31,2025 and the remainder vesting in 36 equal monthly instalments thereafter subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| December 23, 2024 Filed Dec 23, 2024 21:26 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0000950170-24-139598 · ownership.xml · derivative · entry 1 Wadhane Jitendra · CIK 0001941706 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-12-23 F1 · derivative.exercise_date: The shares subject to this option vest in full on December 23, 2025, subject to the Reporting Person's continued employment through the vesting date. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 20:31 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 131,484 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-038097 · ownership.xml · nonDerivative · entry 1 Wadhane Jitendra · CIK 0001941706 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 398,421 F1 · shares: Represents restricted stock units that vest 25% on the first anniversary of March 26, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:16 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-055744 · doc4.xml · nonDerivative · entry 1 Wadhane Jitendra · CIK 0001941706 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,937 F1 · shares: Represents restricted stock units that vest in full on November 14, 2024, subject to the Reporting Person's continued employment through the vesting date. Read SEC document |
| September 27, 2023 Filed Sep 27, 2023 22:37 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | PurchaseCommon Stock | 2,500 | $1.87 | $4,675.00 |
DisclosureSEC source: 0001209191-23-050686 · doc4.xml · nonDerivative · entry 1 Wadhane Jitendra · CIK 0001941706 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,937 F1 · price: The Reporting Person purchased all 2,500 shares of common stock in the open market at a price of $1.87 per share. Read SEC document |
| September 25, 2023 Filed Sep 25, 2023 21:05 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | PurchaseCommon Stock | 5,000 | $1.77 | $8,850.00 |
DisclosureSEC source: 0001209191-23-050495 · doc4.xml · nonDerivative · entry 1 Wadhane Jitendra · CIK 0001941706 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,437 F1 · price: The Reporting Person purchased all 5,000 shares of common stock in the open market at a price of $1.77 per share. Read SEC document |
| September 22, 2023 Filed Sep 22, 2023 23:35 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | PurchaseCommon Stock | 2,500 | $1.74 | $4,349.25 |
DisclosureSEC source: 0001209191-23-050433 · doc4.xml · nonDerivative · entry 1 Wadhane Jitendra · CIK 0001941706 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,437 F1 · price: The Reporting Person purchased all 2,500 shares of common stock in the open market at a price of $1.7397 per share. Read SEC document |
| September 07, 2023 Filed Sep 8, 2023 21:01 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 93,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-048816 · doc4.xml · nonDerivative · entry 1 Wadhane Jitendra · CIK 0001941706 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,937 F1 · shares: Represents restricted stock units that are fully vested. Read SEC document |
| March 24, 2023 Filed Mar 28, 2023 20:45 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to buy) · Derivative | 157,257 | Not disclosed Strike: $2.21 | Not disclosed |
DisclosureSEC source: 0001209191-23-021411 · doc4.xml · derivative · entry 4 Wadhane Jitendra · CIK 0001941706 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,257 Underlying: Common Stock · 157,257 shares Expires 2031-07-30 F3 · derivative.exercise_price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F3 · price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F4 · derivative.exercise_date: These stock options vested 25% on August 23, 2022, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| March 24, 2023 Filed Mar 28, 2023 20:45 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | Disposition to issuerStock Option (Right to buy) · Derivative | 157,257 | Not disclosed Strike: $8.71 | Not disclosed |
DisclosureSEC source: 0001209191-23-021411 · doc4.xml · derivative · entry 3 Wadhane Jitendra · CIK 0001941706 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 157,257 shares Expires 2031-07-30 F3 · derivative.exercise_price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F3 · price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F4 · derivative.exercise_date: These stock options vested 25% on August 23, 2022, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| March 24, 2023 Filed Mar 28, 2023 20:45 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021411 · doc4.xml · nonDerivative · entry 2 Wadhane Jitendra · CIK 0001941706 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,648 F2 · shares: Represents restricted stock units that vest 25% on August 3, 2023, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| March 24, 2023 Filed Mar 28, 2023 20:45 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 29,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021411 · doc4.xml · nonDerivative · entry 1 Wadhane Jitendra · CIK 0001941706 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,041 F1 · shares: Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.